INTRODUCTION
Measles still remains a serious global epidemiological challenge. In 2017, there were 110,000 cases of measles worldwide, mainly in children under the age of five years. Widespread immunisation programmes are effective in epidemic prevention, and according to the estimates of the World Health Organisation (WHO), vaccination produced a decline in the incidence of measles by 80% in 2000-2017. It also helped prevent approximately 21.1 million deaths [1] .
In 1984, the WHO adopted an eradication programme of measles, rubella and congenital rubella syndrome (CRS). It was primarily assumed that the endemic foci of this disease would have been eliminated by 2017 and the incidence of CSR would have been reduced to one case per 100 thousand live births by 2010. In Europe, the European Vaccine Action Plan for 2015-2020 assumed complete elimination of foci of measles and rubella. As for measles, this programme seems to be at least threatened [2] , as suggested by an increase in the incidence of this disease, as noted in 2017-2018. Currently, more debates are being held on the threat of a new measles epidemic rather than on its eradication.
OBJECTIVE
The aim was to illustrate the epidemiological threat and risk for the European continent associated with the increase in the incidence of measles in the past years. The problem was analysed on the basis of epidemiological data from reports and communications of authorities (European Centre for Disease Prevention and Control, as well as from selected literature. The verification was based on a review of Internet websites of public institutions responsible for immunisation programmes in given countries. An attempt is made to shed some more light on the background of this worsening situation, evaluate the functioning of the measles prevention system and consider options to counteract the prevailing situation.
DESCRIPTION OF THE STATE OF KNOWLEDGE
Disease characteristics of measles. Measles is a highly contagious disease caused by a single-stranded RNA virus of the Paramyxoviridae family and Morbillivirus genus [3] . It is an airborne disease that spreads through the sneezing and coughing of infected people, or through contact with secretions of the infected person, such as saliva or nasal secretions [4] . The contagiousness of measles exceeds 95% [5] , which means that practically all people remaining in the same room with an infected individual will contract the disease.
The incubation of measles takes approximately 10-12 days after exposure. The typical signs and symptoms are manifested for approximately 7-10 days, usually including: high fever (over 40°C), coughing, rhinorrhoea and conjunctivitis [4] . On day 2-3 of the disease, small white spots, known as Koplik›s spots, appear on the mucosa of the cheeks at the level of lower molars [6, 7] . The typical rash starts on day 14 and lasts for 3-4 days. A red, flat rash initially develops on the face and then spreads to the rest of the body. This period is characterised by the return of a high fever. The patient's condition deteriorates, with more severe signs and symptoms of upper respiratory tract infection [8, 4] .
Upon recovery, the patient is fully immune. However, measles can cause complications. They mainly develop in immunocompromised or generally neglected children and in children with developmental defects. Measles may cause: gastrointestinal disorders, pneumonia (1-6% of cases; high mortality), myocarditis, encephalitis (1 per 1,000 cases; mortality rate of 15% and permanent neurological deficits in 25% of patients), subacute sclerosing panencephalitis (1-4 per 100 thousand cases; it is a delayed complication that may appear several years after recovery from measles and is manifested with speech disorders, dementia, myoclonus and paresis), inclusion-body encephalitis and ophthalmological diseases: keratitis and retrobulbar optic neuritis leading to blindness. Women may suffer miscarriages [8, 4] .
Measles epidemiology. The mortality rates of measles depend on the region in the world. They do not exceed 0.01% in developed countries, but may reach even 5% in developing countries, with infant mortality in the latter amounting to as much as 30% [4] . In the past several years, the threat of measles in Europe has increased, as has been indicated earlier. Data showing the incidence are presented in Table I .
The deteriorating epidemiological situation concerning measles is mainly driven by a sudden increase in its incidence in the developed countries of Western Europe: France, Germany, United Kingdom and Italy, as well as in Romania. The problem increased throughout the entire decade (2008 -4298 cases; 2012 -8321 cases; 2015 -3969 cases; 2017 -4238 cases; 2018 -9872 cases).
In February 2019, a new measles focus was noted in France in a popular ski resort in Val Thorens. Five new confirmed cases and twenty suspected cases were recorded. New cases of measles observed in Denmark, United Kingdom and Belgium are thought to be linked with this focus, as measles was diagnosed in individuals who stayed in the said ski resort [9] . Although these are all single cases, they must evoke certain unrest as they do prove that the threat of a measles epidemic is real, and the freedom of movement additionally enhances the mechanism of disease proliferation. Moreover, the epidemiological situation in countries neighbouring the EU, such as Russia, Ukraine and Serbia, is another source of threat. In Ukraine, whose situation directly affects Poland, there were 4,800 measles cases in 2017, including five deaths, and 2,100 cases in 2018 [10] . In both Ukraine and Romania, which does belong to the EU, the increase in measles incidence is directly correlated with incorrect implementation of immunisation programmes [10] . The situation is made worse by migration, both within and between countries. It renders prognoses concerning new disease foci impossible, which threatens particularly children and individuals who have not been vaccinated [10] . As may be suspected, the mechanisms of measles proliferation from Ukraine to Poland and from Romania to Bulgaria do exist.
Efficacy of vaccination against measles.
Immunisation is the basic instrument for combating measles. Measles vaccines became available in 1963-1968 [11] . Before that, it was a common disease with a high mortality rate. In the USA, there were approximately 500 thousand cases of measles annually, mainly among children aged 5-9, of whom about 500 were fatal and approximately 150 thousand were complicated. In Poland, up to the year 1974, nearly all children contracted measles, and the number of cases reflected the birth cohort in a given year [12] .
At the beginning of the 1970s, a group led by Maurice Hilleman, an American microbiologist who specialised in vaccinology, developed a combined vaccine against measles, mumps and rubella -the MMR vaccine [11] . Another vaccine used in measles immunisation is MMRV vaccine (against measles mumps, rubella and varicella), which combines an attenuated MMR virus with a varicella vaccine [13] .
Immunisation programmes have been implemented in Europe since the end of the 1960s and vaccination is either mandatory or recommended, with the latter also being reimbursed in most cases. The current situation pertaining to measles vaccination is illustrated in Table 2 .
Measles vaccination is mandatory in only seven of the 28 EU member states. France and Italy have introduced mandatory vaccination only recently due to the dramatic increase in the incidence. In the remaining EU countries, vaccination is recommended and is usually administered in the first dozen or so months of life, and the second dose given several years later. This scheme was implemented in all European countries up to the year 2000, with exception of Moldova and Azerbaijan [2] . In some countries, adults at risk are also recommended to get vaccinated. Vaccination coverage is an indicator of the level of protection against measles in society. It is the percentage of vaccinated people in relation to the entire population (Table 3) .
There is a certain relationship between the increase in the incidence of measles in the past years and the level of vaccination coverage. The countries where this phenomenon is observed are those with the lowest vaccination coverage rates; this concerns Romania and France. Both these countries, alongside Belgium, Germany and Poland, for which the vaccination coverage level is higher, have been classified by the WHO as measles-endemic countries. That is why the WHO programme of measles eradication in the European region will not be successful. This conclusion also results from the fact that, according to the data from October 2016, only 13 of 53 countries belonging to the WHO European region declared complete elimination of measles [12] . Despite the efforts undertaken, Europe is not only not free from the disease, but is threatened with a new epidemic.
This, however, does not change the fact that vaccination remains the most effective tool to combat measles, even more so that there is no effective cure [14] . As an example, it is worth adding that according to the epidemiological data of the Polish National Institute of Public Health-National Institute of Hygiene, the incidence of measles in Poland in 2010-2016 did not exceed 0.35/100,000 people [12] . In 1960, there were 255 deaths due to measles, while a decade after the implementation of the immunisation programme (in 1985), this number decreased to 5. The last fatal case of measles was noted in 1998 [14] . After all, as mentioned earlier, practically every Polish child had contracted measles before vaccines were introduced.
CONCLUSIONS
The epidemiological problem associated with the incidence of measles has become more serious in Europe in the past years. The WHO-adopted programme assuming complete elimination of measles from the European region has turned out to be impossible to complete. Only 13 countries from this region have declared that their territories have been freed from the disease, whereas 7 European countries, including Poland, are considered endemic areas. This Migration from countries with a high percentage of nonvaccinated people and with a high increase in the incidence, such as Ukraine or Romania, to countries where measles prevention is superior, is also a source of threat within the evaluated region. Tightening the immunisation system and administration of vaccines to non-vaccinated migrants in the target country seem to be the only solutions. In a longer perspective, the scientifically unsupported postulates regarding the autism-inducing effect of MMR vaccine in children may be a factor that will sustain the adverse trends in measles epidemiology. Such postulates may drive antivaccination movements, which will have a destructive effect on the immunisation system that is the most effective shield against an epidemic of dangerous contagious diseases, such as measles. 
